他洛昔明 | 17243-68-4

• 物质功能分类: 原料药 - 呼吸系统用药 - 平喘药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 他洛昔明
• 英文名称: N-[4-(2-dimethylamino-ethoxy)-phthalazin-1-yl]-hydroxylamine
• 英文别名: Taloximine；N-[4-[2-(dimethylamino)ethoxy]phthalazin-1-yl]hydroxylamine
• CAS: 17243-68-4
• 化学式: C₁₂H₁₆N₄O₂
• 分子量: 248.285
• InChiKey: GWPPGFBGXMICEH-UHFFFAOYSA-N

物化性质

• 沸点：
  407.7±47.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.5
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Medicinal carbohydrates for treatment of respiratory conditions
  申请人：Australian Biomedical Company Pty Ltd.

  公开号：US10195226B2

  公开（公告）日：2019-02-05

  A method of promoting recovery of cell viability of a damaged respiratory cell. The method includes a step of administering to the cell at least one pharmaceutically acceptable compound, which accelerates sialyglycoconjugate biosynthesis to restore sialylglycoconjugates on the surface of the respiratory cell. Also disclosed are a method and a pharmaceutical composition, both for treating a respiratory condition.

  一种促进受损呼吸细胞活力恢复的方法。该方法包括向细胞施用至少一种药学上可接受的化合物的步骤，该化合物可加速唾液酸糖苷共轭物的生物合成，以恢复呼吸细胞表面的唾液酸糖苷共轭物。还公开了一种方法和一种药物组合物，二者均用于治疗呼吸系统疾病。
• MEDICINAL CARBOHYDRATES FOR TREATMENT OF RESPIRATORY CONDITIONS
  申请人：Australian Biomedical Company Pty Ltd

  公开号：EP2448590B1

  公开（公告）日：2018-10-31
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.